StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) operating KPIs

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)

Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%

AbbVie duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — U.S. net revenues ($M) ($M)

Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues

Latest, FY2025
73
Period ended Dec 31, 2025
Change on a year earlier
-24.0%
96 in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDuodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — U.S. net revenues ($M) ($M)Year on yearSource
FY2025Dec 31, 202573-24.0%Form 10-K (filed 2026-02-20) ↗
FY2024Dec 31, 202496-1.0%Form 10-K (filed 2026-02-20) ↗
FY2023Dec 31, 202397+2.1%Form 10-K (filed 2026-02-20) ↗
FY2022Dec 31, 202295-6.9%Form 10-K (filed 2025-02-14) ↗
FY2021Dec 31, 2021102-1.0%Form 10-K (filed 2024-02-20) ↗
FY2020Dec 31, 2020103+6.2%Form 10-K (filed 2023-02-17) ↗
FY2019Dec 31, 201997+21.2%Form 10-K (filed 2022-02-18) ↗
FY2018Dec 31, 201880+31.1%Form 10-K (filed 2021-02-19) ↗
FY2017Dec 31, 201761+64.9%Form 10-K (filed 2020-02-21) ↗
FY2016Dec 31, 201637–Form 10-K (filed 2019-02-27) ↗

Breakdown

What makes up duodopa (levodopa/carbidopa intestinal gel) [folded into other neuroscience in q1 2026] — u.s. net revenues ($m)

Cite this data

StockData. (2026). AbbVie Duodopa (levodopa/carbidopa intestinal gel) [folded into Other Neuroscience in Q1 2026] — U.S. net revenues ($M) ($M), annual FY2016–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/duodopa_us

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.